Monoclonal antibody therapy achieves modest reduction in recurrence for patients with

[News]

The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43.

More... (https://www.news-medical.net/news/20200529/Monoclonal-antibody-therapy-achieves-modest-reduction-in-recurrence-for-patients-with-HER2-positive-DCIS.aspx)